KLARIFY
LIVE

Serial Number

79975813

Owner

ALK-Abelló A/S

Attorney

Monica Riva Talley

Filing Date

Feb 11, 2022

Add to watchlist:

No watchlists yet
View on USPTO

KLARIFY Trademark

Serial Number: 79975813

KLARIFY is a trademark filed by ALK-Abelló A/S on February 11, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 38 (Telecommunications), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 16 (Paper Goods). The application is currently pending registration.

Owner Contact Info

ALK-Abelló A/S (37 trademarks)

Bøge Allé 6-8
DK-2970 Hørsholm , DK

Entity Type: 99

Trademark Details

Filing Date

February 11, 2022

Registration Date

Not Registered

Published for Opposition

November 12, 2024

Goods & Services

computer software, namely downloadable computer software for medical use for assisting allergy and asthma patients and medical personnel in storing and handling patient data; diagnostic apparatus for testing food, namely, for mold detection; optical sensors for detecting and analyzing the presence of chemicals, toxins, mold and allergens in food, food components and food products; downloadable electronic publications in the nature of magazines and periodicals in the field of allergy and asthma; downloadable electronic magazines and periodicals in the field of allergy and asthma; online downloadable electronic questionnaires on medical issues relating to allergy and asthma; none of the aforesaid goods relating to the cardiovascular field nor for use in continence management, but all solely for use in relation to allergy and asthma

Providing access, with or without subscription, to an e-commerce platform on the Internet giving users access to medical information in the allergy, asthma, allergic rhinitis, allergic asthma, rhinoconjunctivitis, respiratory allergic disease as well as atopic dermatitis and food allergy fields, namely, providing access to telecommunication networks; none of the aforesaid services in relation to the cardiovascular field nor in relation to continence management, but all in relation to allergy and asthma only

Pharmaceutical and veterinary preparations for immunotherapeutic purposes for the treatment of autoimmune diseases; pharmaceutical and veterinary preparations for diagnosis, prevention and treatment of allergy, asthma, allergic rhinitis, allergic asthma, rhinoconjunctivitis, respiratory allergic diseases as well as atopic dermatitis and food allergy; diagnostic preparations for medical purposes, diagnostic reagents and diagnostic testing strips for medical use in the field of allergy, asthma, allergic rhinitis, allergic asthma, rhinoconjunctivitis, respiratory allergic diseases as well as atopic dermatitis and food allergy; eye drops; nose drops, nasal sprays for medical purposes; pharmaceutical preparations for inhalers for the treatment of allergy, asthma, allergic rhinitis, allergic asthma, rhinoconjunctivitis, and respiratory allergic diseases; pharmaceutical preparations in the form of injectable pharmaceuticals, particularly adrenaline, for treatment of anaphylactic reactions; ; probiotic preparations for medical and veterinary use; infant formula, namely, lactose free infant formula and hydrolyzed milk infant formula; additives for infant formula to prevent the development of allergies, namely, dietary supplements; food for babies; diagnostic testing materials for medical use, namely, diagnostic test patch for application to the skin for determining allergies; allergy and asthma testing kits, namely, diagnostic test patch for application to the skin for determining allergic reactions; none of the aforesaid goods for use in the cardiovascular field nor for use in continence management, but all solely for use in relation to allergy and asthma

Printed matter, namely, printed calendars and forms; printed instructional and teaching materials except apparatus in the field of allergy and asthma; printed magazines and periodicals in the field of allergy and asthma; printed questionnaires on medical issues relating to allergy and asthma; none of the aforesaid goods relating to the cardiovascular field nor for use in continence management, but all solely for use in relation to allergy and asthma

Medical services and medical healthcare services; medical consulting services, namely, counselling and information regarding immunotherapy, allergy, asthma, allergic rhinitis, allergic asthma, respiratory allergic diseases as well as atopic dermatitis, food allergy, and anaphylactic reactions; providing patient support relating to immunotherapy as well as to diagnosing, prevention and treatment of allergy, asthma, allergic rhinitis, allergic asthma, rhinoconjunctivitis, respiratory allergic diseases, atopic dermatitis, food allergy, and anaphylactic reactions, also electronically or digitally, including through a website with or without subscription, namely, medical consultations; providing medical information to medical professionals relating to immunotherapy as well as to diagnosing, prevention and treatment of allergy, asthma, allergic rhinitis, allergic asthma, rhinoconjunctivitis, respiratory allergic diseases, atopic dermatitis, food allergy, and anaphylactic reactions, also electronically or digitally, including through a website; medical diagnostic services, namely, medical diagnostic testing, monitoring and reporting services; all of the aforesaid services in relation to allergy, asthma, allergic rhinitis, allergic asthma, rhinoconjunctivitis, respiratory allergic diseases as well as atopic dermatitis, food allergy, and anaphylactic reactions; none of the aforesaid services in relation to the cardiovascular field nor in relation to continence management, but all in relation to allergy and asthma only

Scientific, technological, medical, and pharmacological research services and design relating thereto, namely, scientific research and technological research in the field of manufacturing processes, medical research, pharmaceutical research, pharmaceutical products development and new product design; scientific and medical laboratory services; medical and scientific research, namely, conducting clinical trials for others; computer services, namely, the creation of online communities for registered users to participate in discussions, and engage in social networking; providing a website featuring technology that enables consumers to form virtual communities, engage in social networking and share information regarding food, food components, and food products; all of the aforesaid services in relation to allergy, asthma, allergic rhinitis, allergic asthma, rhinoconjunctivitis, respiratory allergic diseases as well as atopic dermatitis and food allergy; statistical investigations and statistical studies in the fields of allergy, asthma, allergic rhinitis, allergic asthma, rhinoconjunctivitis, respiratory allergic diseases as well as atopic dermatitis and food allergy, namely, medical research; none of the aforesaid services in relation to the cardiovascular field nor in relation to continence management, but all in relation to allergy and asthma only

Filing History

EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Jun 16, 2025 ETOP
PETITION TO DIRECTOR WITHDRAWN
Jun 12, 2025 PCBM
COMMUNICATION RECEIVED FROM PETITIONER
Jun 11, 2025 PETL
ASSIGNED TO PETITION STAFF
May 31, 2025 APET
OPPOSITION PAPERS RECEIVED AT TTAB
May 29, 2025 OPPF
ASSIGNED TO PETITION STAFF
May 29, 2025 APET
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
May 22, 2025 ETOP
TEAS PETITION TO DIRECTOR RECEIVED
May 12, 2025 TPDR
EXTENSION OF TIME TO OPPOSE RECEIVED
Dec 12, 2024 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 12, 2024 NPUB
PUBLISHED FOR OPPOSITION
Nov 12, 2024 PUBO
NEW REPRESENTATIVE AT IB RECEIVED
Nov 1, 2024 NREP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 23, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 4, 2024 CNSA
DIVISIONAL PROCESSING COMPLETE
Aug 29, 2024 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Aug 12, 2024 AITU
DIVISIONAL REQUEST RECEIVED
Jun 17, 2024 DRRR
TEAS REQUEST TO DIVIDE RECEIVED
Jun 17, 2024 ERTD
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Mar 8, 2024 RCSC
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jan 21, 2024 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 3, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jan 3, 2024 OPNR
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Sep 8, 2023 GNS3
LETTER OF SUSPENSION E-MAILED
Sep 8, 2023 GNSL
SUSPENSION LETTER WRITTEN
Sep 8, 2023 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 1, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 31, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 31, 2023 TROA
REFUSAL PROCESSED BY IB
Feb 21, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 30, 2023 RFCS
REFUSAL PROCESSED BY MPU
Jan 30, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 1, 2022 RFCR
NON-FINAL ACTION WRITTEN
Nov 30, 2022 CNRT
ASSIGNED TO EXAMINER
Nov 28, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
Aug 5, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 1, 2022 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jul 30, 2022 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 28, 2022 REPR